EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan
C T
CT
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Wikstrand
C J
CJ
Bigner
D D
DD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D066246:ErbB Receptors / Q000235:genetics / Q000276:immunology*; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use; D009154:Mutation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; C410723:epidermal growth factor receptor VIII; D066246:ErbB Receptors